APMAP is a serum glycoprotein implicated in epithelial‐mesenchymal transition (EMT), which promotes tumor invasion and metastasis,[39] and is considered a potential biomarker for the early diagnosis of CRC.[18] Our analysis reveals that the N‐glycan Hex[4]HexNAc[2]NeuAc[0]Fuc[0] at the N196 site of APMAP (APMAP.N196.4200) is the most significantly altered N‐glycosylation in CRC tissue (Figure 6A). This evidence concerns the gene APMAP and neoplasm.